Skip to content

Potassium Supplementation to Reduce Blood Pressure

Testing the Potential Effect of a Potassium-rich Water Intervention on Blood Pressure in Mild to Moderately Hypertensive Adults: a Double-blind Randomised Controlled Trial

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05412654
Enrollment
40
Registered
2022-06-09
Start date
2022-07-30
Completion date
2023-12-01
Last updated
2024-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prehypertension

Keywords

Potassium, Blood pressure, Systolic, Randomised

Brief summary

The aim of this study is to conduct a definitive trial to assess the efficacy of consuming 1L/day of water rich in potassium to reduce blood pressure in mild to moderately hypertensive adults. The objective is to assess the potential effect of the intervention on reducing systolic blood pressure. This study will comprise of a 4 week, double-blind, parallel randomised controlled trial. Participants will be adults with systolic blood pressure measurements of 130mmHg or greater. The intervention comprises advice to consume bottled water rich in potassium. The comparator will be regular bottled mineral water.This study will recruit 40 people with elevated systolic blood pressure (≥130mmHg) who are not regularly taking antihypertensive medication.

Interventions

DIETARY_SUPPLEMENTHigh potassium water

High potassium water Potassium 6.2 mg/100ml

DIETARY_SUPPLEMENTControl low potassium water

Control water Potassium 0.2 mg/100ml

Sponsors

Suntory Beverage & Food Limited
CollaboratorUNKNOWN
Oxford Brookes University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Intervention model description

Double blinded randomised controlled trial

Eligibility

Sex/Gender
ALL
Age
20 Years to 64 Years
Healthy volunteers
No

Inclusion criteria

* Willing and able to provide informed consent * Between 20 to 64 years old * English speaking * Adults who are not receiving antihypertensive pharmacological treatment * Recent (within 6 months) and latest systolic blood pressure measurement ≥130mmHg and/or diastolic ≥85 mmHg * Have access to internet and equipment for video calling * Able to post samples and equipment to OxBCNH * Physically able to take own body measurements and blood pressure

Exclusion criteria

* Participation in another research study * Unable to read and understand the instructions provided in English * Unable to comply with experimental procedures or not follow testing safety guidelines * People with cardiovascular conditions: heart attack or stroke within the last 3 months, heart failure of grade II New York Heart Association and more severe, or prolonged QT syndrome, angina, arrhythmia or atrial fibrillation. * Uncontrolled type 2 diabetes (HbA1c\> 9%) * Type 2 diabetes controlled using exogenous insulin * Previous or current diagnosis of diabetes complications such as nephropathy, retinopathy and neuropathy. * People with type 1 diabetes * Currently on any medication that may lead to hyperkalemia or fluid retention * Currently being assessed for diagnosis of hypertension (not receiving treatment for high blood pressure) * Already on clinician/HCP supervised diet or restricted diet * They are planning on going away from home (holiday or other) during the 4 week intervention period and will not be able to take water during this time. * Currently prescribed antihypertensive medications, or have been in the last 6 weeks * Chronic kidney disease stage 1 (G1A2 or G1A3), 2 (G2A2 or G2A3), 3a, 3b, 4 or 5 based on UKKA (we will ask whether participants have been diagnosed with kidney disease by a clinician based on this criteria) * They are planning to go on a diet or begin taking supplements containing potassium during the intervention * Pregnant women (including women suspected of being pregnant) and breast-feeding woman.

Design outcomes

Primary

MeasureTime frameDescription
Seated home measured systolic blood pressure mm/HgBlood pressure will be taken at three time points through out the 4 weeks.Blood pressure will me monitored by the participant at home, after detailed instruction are provided by trained researchers over Zoom. Measurements will be taken in duplicate, in the morning and again in the evening (4 times a day total) and the average values will be taken.

Secondary

MeasureTime frameDescription
Seated home measured diastolic blood pressureBlood pressure will be taken at three time points through out the 4 weeksBlood pressure will me monitored by the participant at home, after detailed instruction are provided by trained researchers over Zoom. Measurements will be taken in duplicate, in the morning and again in the evening (4 times a day total) and the average values will be taken.
Qualitative semi-structured, part open ended survey of acceptability of trial and reported barriersThis survey will be administered on the final visit at week 4 of the trial.This survey will be designed by the researchers understand the participant experience of the intervention, in order to optimise any future study expansion. This will include things that worked well and those that did not work as well, during the trial (consumption of the water, convenience, appropriateness of outcome measures, burden on daily activities and lifestyle, etc.)

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026